Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk | Zendy

AI Assistant Blog Pricing

Development of mutation-selective LRRK2 kinase inhibitors as precision medicine for Parkinson's disease and other diseases for which carriers are at increased risk

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.